|FLT3 (ITD) (MV4-11 cells)||FLT3 (WT) (RS4;11 cells)|
|1.1 nM||4.2 nM|
|In vitro (25°C)||DMSO||33.2 mg/mL (59.21 mM)|
|Water||<0.3 mg/mL ( mM)|
|Ethanol||<0.5 mg/mL ( mM)|
|In vivo||15% Captisol||30 mg/mL|
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.1 mM||17.83 mL||89.17 mL||178.35 mL|
|0.5 mM||3.57 mL||17.83 mL||35.67 mL|
|1 mM||1.78 mL||8.92 mL||17.83 mL|
|5 mM||0.36 mL||1.78 mL||3.57 mL|
*The above data is based on the productmolecular weight 560.7. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|MECHANISM OF ACTION||Inhibitor|
|Solubility||DMSO>112mg/mL Water<1mg/mL Ethanol>4mg/mL|
|Storage||at -20°C 3 years Powder|
CYT387 is an inhibitor of Janus kinases JAK1 and JAK2, acting as an ATP competitor with IC50 values of 11 and 18 nM, respectively.
Pexidartinib is a small-molecule receptor tyrosine kinase (RTK) inhibitor of KIT, CSF1R and FLT3 with potential antineoplastic activity.
TCS 359 is a potent inhibitor of FLT3 receptor tyrosine kinase (IC50 = 42 nM) that displays selectivity over a range of other kinases.
AG 490 is a selective inhibitor of EGF receptor tyrosine kinase (IC50 values are 2 and 13.5 μM for EGFR and ErbB2 respectively). Also inhib…
AMG-925 is a potent, selective, and bioavailable FLT3/cyclin-dependent kinase 4 (CDK4) dual kinase inhibitor.
BMS-911543 is an orally available small molecule targeting a subset of Janus-associated kinase (JAK) with potential antineoplastic activity.…
R406 is an orally available spleen tyrosine kinase inhibitor with an IC50 of 41 nM.